Story · Medicine & Biotech

Alnylam reports five-year heart disease benefits from AMVUTTRA

1 outlet · first reported by Longevity.Technology 1d ago

Coverage, in order

  1. 1d ago
    Longevity.Technology UK indie observational
    Alnylam reports five-year heart disease benefits from AMVUTTRA

    Alnylam reported five-year HELIOS-B results at the American Heart Association Scientific Sessions 2026. The analyses, which included a two-year open-label extension, showed that patients treated continuously with AMVUTTRA (vutrisiran) had lower rates of the composite of all-cause mortality and…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.